elimusertib  (TargetMol)

Journal: bioRxiv

Article Title: Glutamine antagonism suppresses tumor growth in adrenocortical carcinoma through inhibition of de novo nucleotide biosynthesis

doi: 10.1101/2025.09.28.674326

Figure Lengend Snippet: a Representative phosphorylated histone H2A.X (γ-H2AX) staining (grey) of SQ BCH-ACC3 implants in C57BL/6J mice treated with JHU-083 or vehicle for nine days (days 6-15 post-implant). Blue, DAPI. Scale bars: 50 μM. b Representative phosphorylated histone H2A.X (γ-H2AX) staining (grey) of SQ NCI-H295R implants in NSG mice treated with JHU-083 or vehicle (days 6-29 post-implant). Blue, DAPI. Scale bars: 50 μM. c,d Assessment of DON and Elimusertib-induced apoptosis (luminescence-based quantification of activated caspase 3/7) in BCH-ACC3 ( c ) and NCI-H295R ( d ) cells, treated for 48 hours (BCH-ACC3) and 96 hours (NCI-H295R). Data are representative of three independent experiments (3-4 technical replicates per experiment). For both cell lines, results were analysed by two-way ANOVA, showing very high statistical significance (p<0.0001) for the effect of DON and Elimusertib on apoptosis, as well as for their interaction (consistent with synergy). Post-hoc pairwise comparisons (Tukey’s) are shown on the graphs. *p<0.05, ****p<0.0001. e Synergistic effects of DON and Elimusertib on ACC cell viability. ACC cell lines were treated with varying doses of DON and Elimusertib for 72 h (BCH-ACC3) or 144 h (NCI-H295R, CU-ACC1 and CU-ACC2), followed by assessment of cell viability. BCH-ACC3, NCI-H295R and CU-ACC2: data are representative of three independent experiments (4-8 technical replicates per experiment). CU-ACC1: Data represent combination (median viabilities) of three independent experiments. Synergy or antagonism was assessed using the SiCoDEA software and applying the Chou-Talalay method Combination Index (CI). Blue color indicates synergy; red color indicates antagonism. Numbers represent log (Combination Index).

Article Snippet: JHU-083 (HY-122218) and elimusertib (HY-101566) were purchased from Medchem Express.

Techniques: Staining, Software

Journal: Cell Reports Medicine

Article Title: Organoid morphology-guided classification for oral cancer reveals prognosis

doi: 10.1016/j.xcrm.2025.102129

Figure Lengend Snippet: Exploring targeted drugs for combination treatment using an organoid model (A) Comparison of drug response by organoid morphology. (B) Comparison of synergy scores for cisplatin by target drug. The Bliss score was calculated using SynergyFinder to evaluate the synergistic effects of BAY1895344, AZD7762, EPZ015666, or everolimus in combination with cisplatin across 27 OSCC organoids, comprising 10 normal-like, 8 dense, and 9 grape-like subtypes. (C) Representative images of Bliss score according to the combination treatment. Normal-like: OC122T-O, dense: SOC34T-O, and grape-like: SOC22T-O. (D) Mean value of Bliss score by morphology. Each experiment was performed in biological quadruplicates. Statistical significance levels: ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 See also and and .

Article Snippet: Bay1895344 hydocholoride , Medchemexpress , Cat#HY-101566.

Techniques: Comparison